French Regulators Approve Ultrasound Trial for Glioblastoma

French regulators approved a Phase I-2 clinical trial of CarThera’s SonoCloud-9 ultrasound device to help treat recurrent glioblastoma.

One of the main causes of recurring tumors is the inability of chemotherapies to cross the blood-brain barrier in sufficient concentrations. The ultrasound device increases the barrier’s permeability, making the chemotherapy more effective. 

CarThera is also hoping for FDA approval to extend the trials to the U.S., in the MD Anderson Cancer Center in Houston and Northwestern Memorial Hospital in Chicago.